Travere Therapeutics, Inc.TVTX

Travere Therapeutics, Inc. Segments Disclosure

10-KFiled Feb 19, 20262 min read
SEGMENT INFORMATION
The Company operates in one business segment focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”), who is the President and Chief Executive Officer. The CODM uses net loss to monitor budget versus actual results in assessing segment performance and the allocation of resources. The Company’s CODM also utilizes the Company’s long-range plan as a strategic tool to allocate resources according to the Company’s strategic objectives. Long-lived assets located outside the U.S. were immaterial as of December 31, 2025 and 2024. The measure of segment assets is reported on the Consolidated Balance Sheets as total assets. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies.
See Note 3 for further discussion of net product sales and Note 4 for discussion of license and collaboration revenues.
The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the years ended December 31, 2025, 2024 and 2023 (in thousands):
Year Ended December 31,
202520242023
Revenue$490,728 $233,175 $145,238 
Less:
Cost of goods sold10,339 7,744 11,450 
Research and development:
External research and development107,036 126,303 142,482 
Internal personnel costs80,091 73,843 84,658 
Other research and development18,884 17,350 17,850 
Total research and development206,011 217,496 244,990 
Selling, general and administrative337,202 264,119 265,542 
In-process research and development— 65,205 — 
Restructuring— 2,438 11,394 
Total other income, net13,551 3,317 12,028 
Income tax provision on continuing operations(988)(120)(223)
Income (loss) from discontinued operations, net of tax24,715 (915)264,934 
Net loss$(25,546)$(321,545)$(111,399)

Historical Timeline

Fiscal YearFiled
2025Feb 19, 2026Showing above
2024Feb 21, 2025
2017Feb 27, 2018

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesLeasesDebtCommitmentsNew Standards